Catalyst Event
Amgen Inc (AMGN) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
4/28/2026, 12:00:00 AM
The U.S. FDA's CDER proposed withdrawing the approval for Amgen's Tavneos on April 28, 2026, citing safety concerns and data manipulation. This is expected to have a high market impact (>=10%) due to the loss of a commercial product and regulatory risks, expected.
Korean Translation
2026년 4월 28일, 미국 FDA CDER이 안전성 및 데이터 조작 문제로 암젠 타브네오스의 승인 철회를 제안함. 제품 상실 및 규제 리스크로 인해 10% 이상의 큰 시장 영향이 예상됨, 예상됨.
Related Recent Events
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q3 2026 earnings release scheduled.
10/15/2026, 12:00:00 AM
ASML Holding NV (ASML) · Earnings Release
ASML is scheduled to release its Q2 2026 financial results on 2026-07-15. The company guided for Q2 sales between €8.4 billion and €9.0 billion, with an estimated price impact of ≥5%, scheduled.
7/15/2026, 12:00:00 AM
Telefonaktiebolaget LM Ericsson (publ) (ERIC) · Earnings Release
Q2 2026 earnings release scheduled.
7/14/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Other
2026 Annual Meeting of Stockholders to be held virtually on 2026-06-17. Medium importance due to ≥5% price impact scheduled.
6/17/2026, 12:00:00 AM
Adobe Inc (ADBE) · Earnings Release
Adobe's Q2 2026 earnings release, which typically results in a medium price impact of 5%, is scheduled.
6/11/2026, 12:00:00 AM
CrowdStrike Holdings Inc (CRWD) · Earnings Release
Q1 fiscal 2027 earnings release scheduled for 2026-06-09. Analysts forecast EPS of $1.07. Low importance due to ≥1% price impact forecasted.
6/9/2026, 12:00:00 AM